Mon Dec 01 16:55:06 UTC 2025: Summary:

The United States and the United Kingdom have struck a new trade deal where the UK will significantly increase its spending on medicines, specifically by 25% over the next three years, and overhaul its drug valuation process. In exchange, the US will eliminate tariffs on UK-made pharmaceuticals, ingredients, and medical technology. The deal also involves changes to the UK’s National Institute for Health and Care Excellence (NICE) appraisal framework and a reduction in the rebate rate for pharmaceutical companies. The agreement aims to encourage investment and innovation in the pharmaceutical sector in both countries, with Bristol Myers Squibb already announcing plans to invest more than $500 million in the UK over the next five years.

News Article:

US and UK Announce Landmark Trade Deal: UK to Boost Pharmaceutical Spending

Washington D.C. – The United States and the United Kingdom have unveiled a new trade agreement that will reshape the pharmaceutical landscape for both nations. The deal, announced Monday, sees the UK committing to a significant 25% increase in spending on medicines within its National Health Service (NHS) for at least the next three years. In return, the US will eliminate all tariffs on UK-manufactured pharmaceuticals, drug ingredients, and medical technology.

“This negotiated outcome pricing for innovative pharmaceuticals will help drive investment and innovation in both countries,” stated US Trade Representative Jamieson Greer.

Beyond the increased spending, the agreement includes an overhaul of the UK’s drug valuation process, specifically within the National Institute for Health and Care Excellence (NICE), which determines the cost-effectiveness of new drugs for the NHS. Sources familiar with the deal indicate changes to NICE’s “quality-adjusted life year” (QALY) calculations.

The move addresses long-standing concerns from the US pharmaceutical industry regarding drug pricing in the UK. President Trump has consistently pushed for European nations to contribute more towards pharmaceutical costs.

British science and technology minister, Liz Kendall, hailed the deal as a catalyst for life sciences investment in the UK. “This vital deal will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives,” she said.

Bristol Myers Squibb has already committed to investing over $500 million in the UK over the next five years as a direct result of the agreement.

While seen as a positive step for pharmaceutical investment, the stock market reaction has been muted. AstraZeneca and GSK saw slight dips in their stock prices, reflecting the complex implications of the deal. The deal also outlines a gradual decrease in the rebate rate for pharmaceutical companies in the UK, reducing to 15% by 2026.

The agreement marks a significant shift in pharmaceutical trade between the US and UK, promising increased investment and access to innovative medicines for both nations.

Read More